Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Company Drug

NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 19, 2024

The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...

Company Deals

Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion

Fineline Cube Jun 19, 2024

Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...

Company Deals

3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion

Fineline Cube Jun 19, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...

Company Medical Device

Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit

Fineline Cube Jun 19, 2024

Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...

Company Drug

Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment

Fineline Cube Jun 19, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Company Drug

Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review

Fineline Cube Jun 19, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets

Fineline Cube Jun 19, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...

Company Drug

Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly

Fineline Cube Jun 19, 2024

Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...

Company Deals

Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal

Fineline Cube Jun 19, 2024

Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...

Company Drug

China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use

Fineline Cube Jun 19, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial

Fineline Cube Jun 19, 2024

AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...

Company Drug

MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae

Fineline Cube Jun 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...

Company Deals

Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal

Fineline Cube Jun 19, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the...

Policy / Regulatory

Gansu Province Introduces Measures for Management of Pharmaceutical Personnel

Fineline Cube Jun 18, 2024

The Gansu Medical Products Administration has issued a set of “Measures for the Management of...

Policy / Regulatory

Guangdong Pharmaceutical Association Expands Off-Label Drug Use Catalogue for 2024

Fineline Cube Jun 18, 2024

The Guangdong Pharmaceutical Association (GDPA) has released the Off-label Drug Use Catalogue for the year...

Company Drug

Envonalkib, Chia Tai Tianqing’s Next-Gen ALK Inhibitor, Wins NMPA Approval for Untreated ALK+ NSCLC

Fineline Cube Jun 18, 2024

Chia Tai Tianqing’s next-generation ALK inhibitor, envonalkib, has received approval from the National Medical Products...

Company Drug

Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting

Fineline Cube Jun 18, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of...

Company

AstraZeneca Restructures County Oncology Team to Enhance Vertical Alignment

Fineline Cube Jun 18, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin...

Company Drug

Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC

Fineline Cube Jun 18, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...

Company Drug

MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention

Fineline Cube Jun 18, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...

Posts pagination

1 … 288 289 290 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.